Identification

Name
Methocarbamol
Accession Number
DB00423  (APRD01102)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)

Structure
Thumb
Synonyms
  • (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
  • Delaxin
  • Methocarbamol
  • Méthocarbamol
  • Methocarbamolum
  • Metocarbamol
  • Metocarbamolo
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methocarbamol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousUnivet Pharmaceuticals Ltd.1988-12-31Not applicableCanada
Methocarbamol OmegaLiquid100 mgIntramuscular; IntravenousOmega Laboratories Ltd2003-07-28Not applicableCanada
PMS-methocarbamol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousPharmascience Inc1990-12-312016-10-28Canada
Robaximol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousMontreal Veterinary Products Inc.1989-12-31Not applicableCanada
RobaxinTablet500 mg/1OralRemedy Repack2012-08-162016-10-13Us
RobaxinTablet, film coated750 mg/1OralStat Rx USA2003-01-20Not applicableUs
RobaxinTablet, film coated750 mg/1OralEndo Pharmaceuticals2011-08-18Not applicableUs
RobaxinTablet, film coated750 mg/1OralPd Rx Pharmaceuticals, Inc.2003-01-202016-12-21Us
RobaxinTablet, film coated500 mg/1OralEndo Pharmaceuticals2012-05-15Not applicableUs
RobaxinInjection100 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical1959-06-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethocarbamolTablet750 mg/1OralCardinal Health2003-01-292017-05-04Us
MethocarbamolTablet, film coated750 mg/1OralProficient Rx LP2015-07-13Not applicableUs
MethocarbamolTablet500 mg/1OralRemedy Repack2012-03-122016-10-26Us
MethocarbamolTablet500 mg/1OralA S Medication Solutions2000-01-012017-06-20Us
MethocarbamolTablet500 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-11-16Not applicableUs
MethocarbamolTablet500 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralDirectrx2015-01-01Not applicableUs
MethocarbamolTablet500 mg/1Oralbryant ranch prepack2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralPreferreed Pharmaceuticals Inc.2010-08-06Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RobaxinTablet500 mgOralPfizer Laboratories Div Pfizer Inc.1958-12-31Not applicableCanada
Robaxin 750Tablet750 mgOralPfizer Laboratories Div Pfizer Inc.1993-12-31Not applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RobaxinInjection100 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical2017-10-17Not applicableUs
International/Other Brands
Bolaxin (Ying Yuan) / Carbaflex (Paill) / Delaxin / DoloVisan (Dr.Kade Pharmaceutische Fabrik) / Fubaxin (Grape King) / Lumirelax (Juvise) / Metocarbamol (AZ Pharma) / Mioflex (Labinco) / Miorel (Cheminter) / Musxan (Pharmasant) / Ortoton (Recordati) / Rebamol (Winston) / Robaxin / Robaxin-750 (Pfizer) / Robinax (Khandelwal) / Sinaxar (Armofar) / Taspan (Honten)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
A.S.A. With Methocarbamol Night-time Extra StrengthMethocarbamol (400 mg) + Acetylsalicylic acid (500 mg)TabletOralPharmetics (2011) Inc.Not applicableNot applicableCanada
Acetaminophen 325mg + Methocarbamol 400mg CapletsMethocarbamol (400 mg) + Acetaminophen (325 mg)TabletOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Acetaminophen 500mg + Methocarbamol 400mg Extra Strength CapletsMethocarbamol (400 mg) + Acetaminophen (500 mg)TabletOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Advil Back PainMethocarbamol (500 mg) + Ibuprofen (200 mg)TabletOralPfizer Laboratories Div Pfizer Inc.Not applicableNot applicableCanada
Analgesic and Muscle RelaxantMethocarbamol (500 mg) + Ibuprofen (400 mg)TabletOralPharmascience Inc2012-03-20Not applicableCanada
Analgesic and Muscle Relaxant CapletsMethocarbamol (500 mg) + Ibuprofen (200 mg)TabletOralTeva2009-11-18Not applicableCanada
Aspirin BackacheMethocarbamol (400 mg) + Acetylsalicylic acid (325 mg)TabletOralBayerNot applicableNot applicableCanada
Aspirin Night-timeMethocarbamol (400 mg) + Acetylsalicylic acid (500 mg)TabletOralBayer Inc Consumer Care2006-05-242010-08-05Canada
Axacet-C1/8Methocarbamol (400 mg) + Acetaminophen (325 mg) + Codeine phosphate (8 mg)TabletOralTechnilab Pharma Inc.Not applicableNot applicableCanada
Axisal-C1/8Methocarbamol (400 mg) + Acetylsalicylic acid (325 mg) + Codeine phosphate (8 mg)TabletOralTechnilab Pharma Inc.Not applicableNot applicableCanada
Categories
UNII
125OD7737X
CAS number
532-03-6
Weight
Average: 241.2405
Monoisotopic: 241.095022595
Chemical Formula
C11H15NO5
InChI Key
GNXFOGHNGIVQEH-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)
IUPAC Name
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
SMILES
COC1=CC=CC=C1OCC(O)COC(N)=O

Pharmacology

Indication

For use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.

Structured Indications
Pharmacodynamics

Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.

Mechanism of action

The mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

TargetActionsOrganism
NCarbonic anhydrase 1
inhibitor
Human
Absorption

Rapid. Onset of action is about 30 minutes after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination

Small amounts of unchanged methocarbamol also are excreted in the urine.

Half life

1.14-1.24 hours

Clearance
  • 0.2 – 0.8 L/h/kg [healthy]
Toxicity

Symptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methocarbamol.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methocarbamol.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methocarbamol.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Methocarbamol.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methocarbamol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methocarbamol.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methocarbamol.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Methocarbamol.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methocarbamol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Methocarbamol.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methocarbamol.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methocarbamol.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methocarbamol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methocarbamol.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methocarbamol.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Methocarbamol.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methocarbamol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methocarbamol.Investigational, Vet Approved
AzelastineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methocarbamol.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methocarbamol.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Methocarbamol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methocarbamol.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methocarbamol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Methocarbamol.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Methocarbamol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Methocarbamol.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methocarbamol.Approved, Investigational
BuprenorphineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Methocarbamol.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methocarbamol.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Methocarbamol.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methocarbamol.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methocarbamol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Methocarbamol.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methocarbamol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methocarbamol.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methocarbamol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methocarbamol.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methocarbamol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methocarbamol.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methocarbamol.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methocarbamol.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methocarbamol.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methocarbamol.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methocarbamol.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Methocarbamol.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Methocarbamol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Methocarbamol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methocarbamol.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methocarbamol.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methocarbamol.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methocarbamol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Methocarbamol.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Methocarbamol.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methocarbamol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methocarbamol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methocarbamol.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methocarbamol.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methocarbamol.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Methocarbamol.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methocarbamol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methocarbamol.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methocarbamol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methocarbamol.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Methocarbamol.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Methocarbamol.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methocarbamol.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methocarbamol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methocarbamol.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Methocarbamol.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Methocarbamol.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methocarbamol.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Entacapone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Methocarbamol.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methocarbamol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methocarbamol.Approved
EthanolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methocarbamol.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Methocarbamol.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methocarbamol.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methocarbamol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Methocarbamol.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Methocarbamol.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Methocarbamol.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methocarbamol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methocarbamol.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methocarbamol.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Methocarbamol.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methocarbamol.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methocarbamol.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methocarbamol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methocarbamol.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methocarbamol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methocarbamol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methocarbamol.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methocarbamol.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Methocarbamol.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methocarbamol.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methocarbamol.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methocarbamol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methocarbamol.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methocarbamol.Approved
HydrocodoneMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Methocarbamol.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methocarbamol.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methocarbamol.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methocarbamol.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methocarbamol.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methocarbamol.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methocarbamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methocarbamol.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methocarbamol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methocarbamol.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Methocarbamol.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methocarbamol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Methocarbamol.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Methocarbamol.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Methocarbamol.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Methocarbamol.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methocarbamol.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methocarbamol.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methocarbamol.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Methocarbamol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methocarbamol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methocarbamol.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methocarbamol.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methocarbamol.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methocarbamol.Approved
MethotrimeprazineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methocarbamol.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methocarbamol.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methocarbamol.Approved
MetyrosineMethocarbamol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Investigational
MirtazapineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methocarbamol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methocarbamol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methocarbamol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methocarbamol.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Methocarbamol.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methocarbamol.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methocarbamol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methocarbamol.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methocarbamol.Approved, Illicit
OrphenadrineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methocarbamol.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methocarbamol.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Methocarbamol.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methocarbamol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methocarbamol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methocarbamol.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.Approved
ParaldehydeMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Methocarbamol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methocarbamol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Methocarbamol.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methocarbamol.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methocarbamol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methocarbamol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Methocarbamol.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Methocarbamol.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methocarbamol.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Methocarbamol.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Methocarbamol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methocarbamol.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methocarbamol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methocarbamol.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Methocarbamol.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.Approved
PramipexoleMethocarbamol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methocarbamol.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methocarbamol.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methocarbamol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methocarbamol.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methocarbamol.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Methocarbamol.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methocarbamol.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Methocarbamol.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Methocarbamol.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Methocarbamol.Investigational
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Methocarbamol.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methocarbamol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Methocarbamol.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Methocarbamol.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methocarbamol.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Methocarbamol.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Methocarbamol.Vet Approved
RopiniroleMethocarbamol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol.Approved
RotigotineMethocarbamol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methocarbamol.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Methocarbamol.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methocarbamol.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methocarbamol.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methocarbamol.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Methocarbamol.Experimental
SuvorexantMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Methocarbamol.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methocarbamol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methocarbamol.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methocarbamol.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methocarbamol.Investigational
ThalidomideMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methocarbamol.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methocarbamol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methocarbamol.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Methocarbamol.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Methocarbamol.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Methocarbamol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methocarbamol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methocarbamol.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methocarbamol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methocarbamol.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Methocarbamol.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Methocarbamol.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Methocarbamol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methocarbamol.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methocarbamol.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Methocarbamol.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Methocarbamol.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methocarbamol.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Methocarbamol.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Methocarbamol.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methocarbamol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Methocarbamol.Vet Approved
ZolpidemMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methocarbamol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methocarbamol.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

General References
  1. Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [PubMed:2253675]
External Links
Human Metabolome Database
HMDB14567
KEGG Drug
D00402
PubChem Compound
4107
PubChem Substance
46507761
ChemSpider
3964
ChEBI
77498
ChEMBL
CHEMBL1201117
PharmGKB
PA164749506
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Methocarbamol
ATC Codes
M03BA53 — Methocarbamol, combinations excl. psycholepticsM03BA03 — MethocarbamolM03BA73 — Methocarbamol, combinations with psycholeptics
AHFS Codes
  • 12:20.04 — Centrally Acting Skeletal Muscle Relaxants
FDA label
Download (121 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPain1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
4RecruitingTreatmentLow Back Pain (LBP)1
4RecruitingTreatmentRib Fractures / Wounds and Injuries1

Pharmacoeconomics

Manufacturers
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Ferndale laboratories inc
  • Forest laboratories inc
  • Able laboratories inc
  • American therapeutics inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Clonmel healthcare ltd
  • Heather drug co inc
  • Hetero drugs ltd
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nylos trading co inc
  • Pharmeral inc
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Solco healthcare us llc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Tablicaps inc
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous100 mg/mL
Injection, solutionIntramuscular; Intravenous100 mg/mL
Injection, solutionIntramuscular; Intravenous1000 mg/10mL
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
TabletOral500 mg
Tablet, film coatedOral750 mg/1
TabletOral750 mg
LiquidIntramuscular; Intravenous100 mg
TabletOral
Prices
Unit descriptionCostUnit
Robaxin-750 750 mg tablet2.48USD tablet
Robaxin 100 mg/ml vial2.2USD ml
Robaxin-750 tablet1.99USD tablet
Robaxin 500 mg tablet1.68USD tablet
Methocarbamol powder0.95USD g
Methocarbamol 750 mg tablet0.49USD tablet
Methocarbamol 500 mg tablet0.38USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)93 °CPhysProp
water solubility7200 mg/L (at 25 °C)CHEM INSPECT TEST INST (1992)
logP0.61CHEM INSPECT TEST INST (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.21 mg/mLALOGPS
logP0.63ALOGPS
logP0.45ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.01 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.07 m3·mol-1ChemAxon
Polarizability24.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9638
Blood Brain Barrier+0.5747
Caco-2 permeable-0.6689
P-glycoprotein substrateNon-substrate0.6452
P-glycoprotein inhibitor INon-inhibitor0.9411
P-glycoprotein inhibitor IINon-inhibitor0.8887
Renal organic cation transporterNon-inhibitor0.9105
CYP450 2C9 substrateNon-substrate0.8431
CYP450 2D6 substrateNon-substrate0.7658
CYP450 3A4 substrateNon-substrate0.606
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9302
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9066
CYP450 3A4 inhibitorNon-inhibitor0.9338
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9542
Ames testNon AMES toxic0.5776
CarcinogenicityNon-carcinogens0.9406
BiodegradationNot ready biodegradable0.8358
Rat acute toxicity2.2930 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.984
hERG inhibition (predictor II)Non-inhibitor0.9411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02t9-0900000000-97aeacf66e8410c23139
MS/MS Spectrum - , positiveLC-MS/MSsplash10-02t9-2900000000-df41a784aa756b8e064d

Taxonomy

Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Alkyl aryl ethers / Carbamate esters / Secondary alcohols / Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Phenoxy compound / Anisole / Methoxybenzene / Alkyl aryl ether / Monocyclic benzene moiety / Carbamic acid ester / Carbonic acid derivative / Secondary alcohol / Ether / Alcohol
show 9 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carbamate ester, aromatic ether, secondary alcohol (CHEBI:77498)

Targets

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. [PubMed:1460006]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18